Skip to main content

Table 3 FDA status and pharmacokinetic characteristics of new carbapenems.

From: New treatment options against gram-negative organisms

      Active against
Drug FDA status Dose Administration Half-life (h) P. aeruginosa MRSA VRE PRP
Ertapenem Approved 1 g qd i.v. 4 - - - -
Doripenem Approved 500 mg tid i.v. 1 + - - +
Biapenem Phase II 300 mg bid i.v. 1.03 + - - +
Panipenem Approved in Japan, China and Korea 0,5/0,5 g bid i.v. 1.10-0.7 - - - +
Tebipenem Phase II 4 or 6 mg/kg bid oral U - - U +
Tomopenem Phase II 700 mg i.v. 1.7 + +   
Razupenem Phase II U i.v. U + + +  
Trinems   U U U - U +/- -
  1. i.v.: intravenous; MRSA: methicillin-resistant S. aureus; PRP: penicillin-resistant pneumococci; U: unknown; VRE: vancomycin-resistant enterococci; +: active; -: non active; +/-: data only on small number of strains